New tablet could scratch the itch for dialysis patients

NCT ID NCT07098351

Recruiting now Symptom relief Sponsor: Guangdong Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether nalfurafine hydrochloride tablets can safely reduce moderate-to-severe itching in people undergoing peritoneal dialysis. About 93 participants will take the drug daily for up to 4 weeks, and their itch levels will be measured using a simple 0-to-10 scale. The goal is to see if this medication offers meaningful relief for a common and distressing symptom.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nalfurafine hydrochloride (orally disintegrating tablet)
What this could lead to: If it works, this could provide a new treatment option for severe itching in people on peritoneal dialysis, improving their comfort and daily life.
What could go wrong: This is a small, early-phase trial with no placebo group, so results may not be definitive. The drug may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE EVENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE EVENT CHRONIC KIDNEY DISEASE-ASSOCIATED ITCH MODERATE-TO-SEVERE PRURITUS PERITONEAL DIALYSIS

Contacts and locations

Locations

Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.